

# The predictive value of PET-CT and PET-DW-MRI early during chemoradiotherapy for head and neck cancer

No registrations found.

|                              |                            |
|------------------------------|----------------------------|
| <b>Ethical review</b>        | Positive opinion           |
| <b>Status</b>                | Recruiting                 |
| <b>Health condition type</b> | -                          |
| <b>Study type</b>            | Observational non invasive |

## Summary

### ID

NL-OMON28050

### Source

Nationaal Trial Register

### Brief title

PREDICTION

## Sponsors and support

**Primary sponsor:** Prof. dr. R. de Bree

Department of Otolaryngology/ Head and Neck surgery

VU University Medical Center

1081 HV Amsterdam

+31204443689

+31204443688

r.bree@vumc.nl

**Source(s) of monetary or material Support:** Initiator

## Intervention

## Outcome measures

### Primary outcome

To investigate the diagnostic value of FDG-PET-CT and DW-MRI (EPI and non-EPI technique)

applied 2 weeks after the start of primary chemoradiotherapy for HNSCC to predict locoregional response in the primary tumor and cervical node metastases.

## Secondary outcome

To determine the value of different criteria, related to the primary objective, such as:

- FDG uptake level pretreatment (on PET-CT and PET-MRI)
  - Residual FDG uptake level after 14 days of therapy (on PET-CT and PET-MRI)
  - Change of FDG uptake (on PET-CT and PET-MRI)
  - b=1000 signal intensity and ADC level pretreatment (for both EPI- and non-EPI-technique)
  - Residual b=1000 signal intensity and ADC level after 14 days of therapy (for both EPI- and non-EPI-technique)
  - Change of b=1000 signal intensity and ADC (for both EPI- and non-EPI-technique)
- FDG-uptake levels obtained from PET-CT and PET-MRI will be compared (taking into account the different time intervals between FDG-injection and scanning)

## Study description

### Background summary

Rationale: The last decade, radiotherapy with or without chemotherapy has become an organ sparing treatment modality for functionally irresectable head and neck squamous cell carcinoma (HNSCC) to retain the best quality of life. The early identification of non-responders to chemoradiation would spare a substantial number of patients from the morbidity of radiotherapy with or without chemotherapy and the increased risk of complications associated with salvage surgery. Moreover, this may lead to overall improvements in survival if radiotherapy can (still) be used, when indicated, as a post-operative modality.

Objectives: (1) To determine the diagnostic value of FDG-PET-CT and two diffusion-weighted MRI-techniques (EPI and non-EPI) performed pre-treatment and in the early phase of treatment in predicting the locoregional response to chemoradiation for HNSCC. (2) To determine the feasibility of PET-MRI in this population.

Study design: Prospective, single institute, observational study of 20 consecutive patients.

Study population: Patients with advanced technically resectable HNSCC scheduled for primary chemoradiation with curative intent.

Intervention: 2 FDG-PET-CT and 2 PET-DW-MRI scans (including diffusion-weighted images)

prior to therapy and during therapy (2 weeks after the start of radiotherapy).

Main study parameters/endpoints: Criteria for predicting locoregional response and accuracy of FDG-PET-CT and DW-MRI (EPI and non-EPI technique). Feasibility of PET-MRI.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: In standard clinical practice these patients will undergo DW-MRI and FDG-PET-CT pretreatment for staging of the tumor. In this protocol, these patients will undergo one extra PET (part of pretreatment MRI), one extra FDG-PET-CT and one extra PET-DW-MRI extra (in the early phase of treatment) in context of the study. The DW-MRI will be made on the PET-MRI-scanner two hours after FDG-injection for PET-CT. A new PET will be made resulting in an extra 30 minutes scanning time. Radiation exposure due to repeated PET-CT scanning (10 mSv) is negligible compared to the radiation therapy of these patients. For PET-MRI no extra FDG will be administered.

These patients have no benefit of the extra FDG-PET-CT and PET-DW-MRI, as these scans are not used for clinical practice and treatment related decisions. In the future patients may benefit from FDG-PET-CT and PET-DW-MRI during treatment in stopping futile (low chance to cure) chemoradiation and switch to surgical treatment with still some adjuvant radiotherapy available.

## **Study objective**

The last decade, radiotherapy with or without chemotherapy has become an organ sparing treatment modality for functionally irresectable head and neck squamous cell carcinoma (HNSCC) to retain the best quality of life. The early identification of non-responders to chemoradiation would spare a substantial number of patients from the morbidity of radiotherapy with or without chemotherapy and the increased risk of complications associated with salvage surgery. Moreover, this may lead to overall improvements in survival if radiotherapy can (still) be used, when indicated, as a post-operative modality.

## **Study design**

Pretreatment: FDG-PET-CT and PET-DW-MRI

2 weeks after the start of radiotherapy: FDG-PET-CT and PET-DW-MRI

## **Intervention**

Two FDG-PET-CT and two PET-DW-MRI scans (including diffusion-weighted images) prior to therapy and during therapy (2 weeks after the start of radiotherapy).

## **Contacts**

### **Public**

Department of Otolaryngology/ Head and Neck surgery

VU University Medical Center

C.S. Schouten  
Amsterdam 1081 HV  
The Netherlands  
+31204440954

**Scientific**

Department of Otolaryngology/ Head and Neck surgery  
VU University Medical Center

C.S. Schouten  
Amsterdam 1081 HV  
The Netherlands  
+31204440954

## Eligibility criteria

### Inclusion criteria

- Squamous cell carcinoma
- Oral cavity, pharynx or larynx
- T2, T3 or T4
- Resectable (technically)
- Primary chemoradiation (with curative intent)

### Exclusion criteria

- Age < 18 years
- Pregnancy
- Patients carrying a pacemaker, or unable to undergo an MRI

## Study design

## Design

|                     |                            |
|---------------------|----------------------------|
| Study type:         | Observational non invasive |
| Intervention model: | Other                      |
| Allocation:         | Non controlled trial       |
| Masking:            | Open (masking not used)    |
| Control:            | N/A , unknown              |

## Recruitment

|                           |             |
|---------------------------|-------------|
| NL                        |             |
| Recruitment status:       | Recruiting  |
| Start date (anticipated): | 01-09-2013  |
| Enrollment:               | 20          |
| Type:                     | Anticipated |

## Ethics review

|                   |                  |
|-------------------|------------------|
| Positive opinion  |                  |
| Date:             | 07-08-2013       |
| Application type: | First submission |

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

| Register | ID     |
|----------|--------|
| NTR-new  | NL3946 |

**Register**

NTR-old

Other

ISRCTN

**ID**

NTR4111

MEC : 2013/191

ISRCTN wordt niet meer aangevraagd.

## Study results